www.remora-biotech.ch Open in urlscan Pro
34.149.87.45  Public Scan

Form analysis
0 forms found in the DOM

Text Content

top of page
Skip to Main Content


THE ROLE OF BOARD MEMBERS

 * Board members are entrepreneurial executives with extensive experience in
   asset management, startups/SMEs and global corporations

 * Board controls investment, budget, nomination, compensation, audit, and
   guarantees alignment of interests

 * Board is regulated by an organization charter

 * Board operates its own internal processes and procedures based on EVCA
   professional standards

THE ROLE OF BOARD MEMBERS

 * Board members are entrepreneurial executives with extensive experience in
   asset management, startups/SMEs and global corporations

 * Board controls investment, budget, nomination, compensation, audit, and
   guarantees alignment of interests

 * Board is regulated by an organization charter

 * Board operates its own internal processes and procedures based on EVCA
   professional standards



 * Home

 * Our Team

 * Primary Focus

 * Assets

 * News

 * Contact us

 * Items

 * More


Use tab to navigate through the menu items.

Log In




IMMUNOTHERAPY VENTURES


ABOUT US

Immunotherapy has an immense and growing impact on medicine and society :
vaccines against pandemics, monoclonal antibodies – the most successful class of
drugs, breakthrough cures of cancer and autoimmune diseases, and new hopes to
fight degenerative diseases.



As immunologists and serial entrepreneurs, we contributed, at our small
individual scale, to this biopharmaceutical revolution driven by immunology. 



We now join forces at Remora Biotech to leverage our entrepreneurial experience
and, thanks to our supporting investors, to scale-up our ability to nurture and
develop innovative life-changing immunotherapies. 



With our growing team and network of academic partners, business-oriented
scientists, patent experts, drug developers and finance professionals, we
create, finance, and manage a portfolio of daughter companies from discovery to
clinical proof-of-concept. We aim at maximizing their odds of success and their
strategic value for pharma partners while keeping capital efficient. 

 

We offer frequent investment opportunities in our holding company Remora Biotech
and in our participations to investors keen to gain exposure to this high-growth
and high-impact sector, under the leadership of seasoned entrepreneurs. 

contact


RECENT NEWS

Fastox awarded Innovation of the Year at the 2023 IMCAS World Congress.

Telix Recognised as Company of the Year at AusBiotech + Johnson & Johnson
Innovation Industry Awards

First Patient Enrolled in ProstACT TARGET Study




Legal Disclaimer
 * 

bottom of page
AcceptDecline AllSettings
We use cookies on our website to see how you interact with it. By accepting, you
agree to our use of such cookies.Privacy Policy